PubRank

Michiel E H Hemels

Author PubWeight™ 10.85‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Meta-analysis of placebo rates in major depressive disorder trials. Ann Pharmacother 2003 0.97
2 Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Vaccine 2004 0.96
3 Advanced cutaneous malignant melanoma: a systematic review of economic and quality-of-life studies. Value Health 2008 0.94
4 Paternal organic solvent exposure and adverse pregnancy outcomes: a meta-analysis. Am J Ind Med 2005 0.92
5 Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. Nord J Psychiatry 2013 0.88
6 A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005 0.85
7 Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom. Ann Pharmacother 2006 0.81
8 Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece. Ann Gen Psychiatry 2012 0.80
9 A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2005 0.80
10 An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitate. Ann Pharmacother 2012 0.78
11 Utilities for asthma and COPD according to category of severity: a comprehensive literature review. J Med Econ 2015 0.77
12 Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland. J Med Econ 2013 0.77
13 A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther 2005 0.77
14 Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic. J Med Econ 2013 0.75
15 Validation of an economic model of paliperidone palmitate for chronic schizophrenia. J Med Econ 2013 0.75